Subject: The National Centre for Research and Development recommended co-funding of the project dedicated to the development of a drug based on GPR40 receptor agonists in the treatment of neuropathic pain<\/p>\n
Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) \u2013 confidential information, time: 4:27 PM<\/p>\n
Content of the report:<\/p>\n
Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) wishes to announce that on January 18, 2021 it received information that the Company\u2019s application for co-funding of the project entitled \u201cDevelopment and implementation into clinical trials and the company\u2019s activities of a drug based on GPR40 receptor agonists in the treatment of neuropathic pain (GRAPPA)\u201d, submitted to a competition under the Smart Growth Operational Programme 2014-2020, measure 1.1\/submeasure 1.1.1. was recommended for co-funding by the National Centre for Research and Development. The total project cost was estimated at PLN 42.3 million and the recommended value of the co-funding is PLN 22.2 million.<\/p>\n
Chronic pain conditions are experienced by patients suffering from physical injuries and lifestyle diseases which are increasingly prevalent. The latest scientific discoveries have confirmed that GPR40 agonists play a key role in the modification of inflammatory and neuropathic pain.<\/p>\n
The final objective of this project is to evaluate the drug candidate in the treatment of neuropathic pain as part of phase II clinical trials.<\/p>\n
The CPL207208 compound, also known as CPL\u2019208, is a specific GPR40 receptor agonist. It is being developed by Celon Pharma S.A. for treatment of type 2 diabetes and diabetic neuropathies and has successfully completed phase I clinical trials.<\/p>\n
The final amount of the co-funding may change. The Company will announce the conclusion of the co-funding agreement in a separate current report.<\/p>\n","protected":false},"excerpt":{"rendered":"